title: FDA updates Gleevec label for GIST patients.
authors.forename: Charlie
authors.initials: C
authors.lastname: Schmidt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004348:Drug Labeling / Q000592:standards*; D005060:Europe; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D009154:Mutation / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D010879:Piperazines / Q000008:administration & dosage*; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects / Q000235:genetics*; D011743:Pyrimidines / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit